Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.6K
Cancer Vaccines01:30

Cancer Vaccines

410
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
410
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cancer Prevention/Interception Agent Development.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A <sup>1</sup>H and <sup>31</sup>P Magnetic Resonance Spectroscopy Study.

International journal of molecular sciences·2025
Same author

Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia.

Cancer prevention research (Philadelphia, Pa.)·2024
Same author

Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.

Journal of cell science·2024

相关实验视频

Updated: Jul 23, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

在使用小分子或疫苗的RAS突变瘤模型中进行初级预防和拦截研究.

Konstantin H Dragnev1, Ronald A Lubet2, Mark Steven Miller2

  • 1Dartmouth Cancer Center, Lebanon, New Hampshire.

Cancer prevention research (Philadelphia, Pa.)
|July 19, 2023
PubMed
概括

准RAS突变癌症是一项挑战,但预防和拦截是有希望的. 各种药物,包括葡萄糖皮质激素,RXR激动剂和COX抑制剂,可以有效地预防或拦截不同器官的RAS突变瘤.

更多相关视频

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K

相关实验视频

Last Updated: Jul 23, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K

科学领域:

  • 在瘤学瘤学.
  • 预防癌症 预防癌症
  • 分子生物学分子生物学

背景情况:

  • 对RAS突变癌症的治疗向仍然很困难.
  • 预防和拦截策略 (侵袭前或侵袭前阶段的治疗) 显示出临床前有希望的结果.
  • RAS通路突变是各种人类癌症的常见驱动因素.

研究的目的:

  • 评估各种药物的有效性,以预防或拦截不同器官的RAS突变瘤.
  • 探索非RAS特异性药物在癌症预防和拦截方面的潜力.
  • 调查组合疗法,以加强预防RAS驱动的癌症.

主要方法:

  • 使用了临床前癌症模型,包括A/J小鼠肺部,鼠标阿佐基甲诱导的结肠和N-nitroso-N-methylurea诱导的鼠标乳腺模型.
  • 服用各种药物,如葡萄糖皮质激素,视网膜X受体 (RXR) 激动剂,循环氧化原酶 (COX) 1/2抑制剂,EGFR抑制剂和选择性雌激素受体调节剂.
  • 在KRAS突变,HRAS突变和野生型瘤环境中评估瘤发育和对治疗的反应.

主要成果:

  • 葡萄糖皮质类药物和RXR激动剂在预防/拦截KRAS突变的肺瘤方面是有效的,无论具体突变如何.
  • COX 1/2 抑制剂和二甲基诺尼丁在预防/拦截KRAS突变和野生型结肠瘤方面表现出有效性.
  • 与COX和EGFR抑制剂的联合治疗在转基因小鼠中几乎消除了胰腺瘤.
  • 选择性雌激素受体调节剂,芳香酶抑制剂,EGFR抑制剂和RXR激动剂在HRAS突变的乳腺瘤中有效,而蒂法尼布则优先抑制HRAS突变瘤.

结论:

  • 许多不直接向RAS通路的药物在预防或拦截RAS突变瘤方面表现出器官特异性疗效.
  • 预防和拦截是管理RAS驱动癌症的可行策略.
  • 未来的研究可以探索针对KRAS的疫苗,作为另一种预防方法.